PDCD1 and neoplasm: Accordingly, a novel dual inhibitor of cMET and PD1 has shown superior anti-tumor efficacy with solid anti-proliferative and anti-metastatic effects compared to monotherapy with PD1 inhibitors alone in tumor cell lines and in a mouse model with liver cancer (65).